DOI QR코드

DOI QR Code

HIV/AIDS Management: Dolutegravir Based Antiretroviral Drug Therapy

  • Received : 2020.04.15
  • Accepted : 2020.09.05
  • Published : 2020.09.30

Abstract

HIV/AIDS disease still remain a global pandemic and it's management has undergone series of treatment changes and improvement although there is still no permanent cure.Dolutegravir belongs to a group of HIV drugs called integrase inhibitors. Integrase inhibitors block an HIV enzyme called integrase. By blocking integrase, integrase inhibitors prevent HIV from multiplying and can reduce the amount of HIV in the body.Dolutegravir combination based regimen has turned out to be very effective (antiviral) with negligible rare side effects on clients. This drug (Dolutegravir based regimen) combination has successfully increased the appetite for food of all the clients, unlike others and has shown to reduce viral load in the most shortest period ever. It can be deduced that development of resistant mutant virus will be reduced if not eliminated with dolutogravir based regimen.The role of Continuous adherence counseling has shown to improve clients treatment management. It is important to note that the availability of food has direct effect on the economic status or financial weight on the client. Hence the progress that is increase in body mass index (BMI) is a direct impact of the availability of food for the clients.

Keywords

References

  1. Collier, A.C., Coombs, R.W., Schoenfeld, D.A., Bassett, R.L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., & McAuliffe, V.J. (1996). Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med, 334, 1011-1017 https://doi.org/10.1056/NEJM199604183341602
  2. D'Aquila, R.T., Hughes, M.D., Johnson, V.A., Fischl, M.A., Sommadossi, J.P., Liou, S.H., Timpone, J., Myers, M., Basgoz, N., Niu, M. (1996). Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double- blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med, 124, 1019-1030 https://doi.org/10.7326/0003-4819-124-12-199606150-00001
  3. Eric, J. A., and Hazuda, D. J. (2012). HIV-1 Antiretroviral Drug Therapy Cold Spring Harb Perspect Med. 2(4), a007161. doi: 10.1101/cshperspect.a007161
  4. Staszewski, S., Miller, V., Rehmet, S., Stark, T., De, C.J., De, B.M., Peeters, M., Andries, K., Moeremans, M., De, R.M. (1996). Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS10: F1-F7 https://doi.org/10.1097/00002030-199605000-00001
  5. U.S. Food and Drug Administration (FDA) (2000). Dolutogravir dosage and effect. Retrieved May 22, 2019, from http://www.AIDSinfo.html